Is Intrathecal Methotrexate Necessary in the Treatment of Primary CNS Lymphoma?

@article{Khan2002IsIM,
  title={Is Intrathecal Methotrexate Necessary in the Treatment of Primary CNS Lymphoma?},
  author={Raja Basit Khan and W Shi and Howard T. Thaler and Lisa M DeAngelis and Lauren Eileen Abrey},
  journal={Journal of Neuro-Oncology},
  year={2002},
  volume={58},
  pages={175-178}
}
Systemic high-dose methotrexate (HD-MTX) is the most effective chemotherapeutic agent in the treatment of primary central nervous system lymphoma (PCNSL). Leptomeningeal involvement is common and intrathecal methotrexate (IT-MTX) is frequently used in combination with HD-MTX, but its benefits are not established. Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity. 
51 Citations
11 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 11 references

Similar Papers

Loading similar papers…